Filing Flows › QuidelOrtho (QDEL) › Guidance & outlook
QuidelOrtho (QDEL) guidance and outlook
QuidelOrtho (QDEL) lowered its guidance on Nov 3, 2026: EBITDA $540M–$545M for FY2026; EBITDA margin 21% for FY2026; EPS $0.65–$0.70 for FY2026. QuidelOrtho's 10-Q filed Nov 4, 2026 makes 20 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EBITDA | FY2026 | $540M–$545M | lowered |
| EBITDA margin | FY2026 | 21% | lowered |
| EPS | FY2026 | $0.65–$0.70 | lowered |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity for clinicians and patients to help create better health outcomes.
- In February 2024, we initiated a wind-down plan to transition out of the U.S. donor screening portfolio.
- While we wind-down this U.S. donor screening portfolio, we will continue to support our existing customers and honor our contractual commitments.
- In the second quarter of 2025, we launched the Optimization Plan that aims to (i) realign our costs with our long-term revenue expectations, (ii) drive operational efficiencies in manufacturing and distribution cost bases and (iii) support and align with our strategy to invest in key priorities.
- The cumulative pre-tax charges to be incurred by us to implement the Optimization Plan are expected to be approximately $100 million through 2027, with charges of $36.7 million incurred to date.
- Additionally, in the second quarter of 2025, we announced a strategic refocusing of our Molecular Diagnostics business, including our plan to discontinue the development of the SAVANNA platform, which exit we expect to be substantially complete by the first half of 2027.
- We expect the program to deliver over $80 million in annual savings in 2027 and to record approximately $30 to $35 million in one-time restructuring charges in the fourth quarter of 2026.
- Although the Company plans to, and we have thus far, substantially offset such incremental costs through operating measures, including supply chain adjustments, current and future tariffs could have a material adverse effect on our business, financial condition and results of operations, including through increased supply chain costs.
- We expect overall demand for our non-respiratory and respiratory products to continue to fluctuate as a result of a number of factors, including supply, emergence and spread of new variants, and the demands of the respiratory season, which are variable and typically more prevalent during the fall and winter.
- Centers for Medicare & Medicaid Services ("CMS") transition guidance, SOFIA Combo tests that we distribute prior to the termination date may continue to be sold by our distributor customers and used by health care providers through their labeled expiration dates under the same circumstances in a manner consistent with the EUA in effect prior to the termination date.
- Based on current information, we believe that any business impact will not be material to our total annualized revenue.
- We expect to continue to evaluate strategic opportunities to (i) expand our product lines and services, production capabilities, technologies and geographic footprint and address other business challenges and opportunities, and (ii) rationalize and consolidate facilities with the goal of improving our long-term results.
QuidelOrtho's latest quarter
QuidelOrtho, Q3 2026: revenue $619M (-12% year over year), operating margin -1.2%, net loss $53.8M, operating cash flow $19.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did QuidelOrtho raise or lower its guidance?
QuidelOrtho (QDEL) lowered its guidance on Nov 3, 2026: EBITDA $540M–$545M for FY2026; EBITDA margin 21% for FY2026; EPS $0.65–$0.70 for FY2026.
What does QuidelOrtho expect?
With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity for clinicians and patients to help create better health outcomes. In February 2024, we initiated a wind-down plan to transition out of the U.S. donor screening portfolio. While we wind-down this U.S. donor screening portfolio, we will continue to support our existing customers and honor our contractual commitments.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.